News/Events
Subscribe to get latest news
News
Flamingo Therapeutics Announces Participation in Upcoming Investor Conferences
Flamingo Therapeutics (“Flamingo”) announced today its participation in the following upcoming investor conferences:
Flamingo Therapeutics Announces First Patients Dosed in the United Kingdom and Korea in ongoing Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC)
Flamingo Therapeutics (“Flamingo”) today announced that the PEMDA-HN trial has expanded beyond the United States into the UK and Korea.
Flamingo Therapeutics Announces Poster Presentation at EACR 2024 Congress on FLM-7523 (FTX-001), a First-in-Class Inhibitor of the Long Non-Coding RNA MALAT1
Flamingo Therapeutics (“Flamingo”) today announced a poster presentation on FLM-7523 (also referred to as FTX-001) at the Annual Congress of the European Association for Cancer Research (EACR) 2024 Congress, being held in Rotterdam, Netherlands from June 10-13, 2024.
Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC)
Flamingo Therapeutics (“Flamingo”) today announced the presentation of a Trial-in-Progress poster at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO 2024) taking place in Chicago, Illinois.
Flamingo Therapeutics Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Danvatirsen in Phase 1 for AML/MDS Cancers
Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in an Investigator-initiated Trial (IIT) evaluating the safety and efficacy of danvatirsen in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who have relapsed or are refractory to frontline therapy.
Flamingo Therapeutics Announces Participation in Upcoming Investor and Industry Conferences
Flamingo Therapeutics (“Flamingo”) today announced its participation in the following upcoming investor and industry conferences:
Media
Can Cancer Be Treated by Changing Its Cells?
In 2017, Karen Kostroff, a renowned oncology surgeon at Northwell Health in the New York Metropolitan area added a new talking point ...
The dark matter of the genome: Flamingo Therapeutics taps potential of mysterious RNA for cancer therapies
Flamingo Therapeutics was born out of a collaboration between three partners in Flanders – VIB, UGent and KU Leuven – and the University of Michigan ...
Leuvense biotechstarter mikt op nieuwe kankertherapieën
Flamingo werd vorig jaar opgericht als spin-off van het Vlaams Instituut voor Biotechnologie (VIB), de KU Leuven en UGent, maar opereerde ...
Ionis collaborator Flamingo is ready to take flight with 3 antisense drugs in the clinic and mysterious RNA in its sights
As the biggest name in antisense technology, Ionis has long focused on testing the interplay between oligonucleotides and RNA for therapeutic effect ...